Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan (PSP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting equity transactions related to executive compensation plans.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details the vesting and release of Ordinary shares and American Depositary Receipts (ADRs) for specific executives following a three-year measurement period and the dividend paid on April 7, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure and Transparency Rules 3.1.4R(1)(a) regarding the vesting of PSP awards for named individuals.
Important Facts for Investors
- The filing confirms the vesting of Performance Share Plan awards for 15 named executives and directors.
- Vesting percentages for the reported period were either 35.0% or 17.5% depending on the individual.
- The transactions involve the release of Ordinary shares and ADRs following the dividend payment on April 7, 2011.
- This report does not contain financial performance data for the company.